Motilal Oswal Financial Services (MOFSL) has initiated coverage on Aster DM Quality Care with a 'Buy' rating and a target price of ₹910, implying around 22% upside from the stock's current level. As per the latest reports, the stock was trading at ₹745.65, down 0.23% on Tuesday, with the stock showing 24% gains year-to-date despite weak market sentiment due to US-Iran conflict and elevated crude oil prices. The recommendation is based on the company's strategic merger with QCIL and strong operational fundamentals, with the brokerage noting that Aster DM Quality Care has been on a strong run since hiving off its GCC business in April 2024 to focus entirely on India.
Despite broader market challenges, Aster DM Quality Care has delivered exceptional returns with 24% gains year-to-date, significantly outperforming the Sensex's over 14% decline. The stock has demonstrated remarkable resilience, hitting a 52-week high of ₹890.95 on 10 August after recovering from a 52-week low of ₹519.80 on 4 February. On longer timeframes, the stock has delivered multibagger returns of 130% over three years and 250% over five years, as per BSE data. However, on monthly scale, the stock is down about 1% in September after an 8% fall in August, reflecting recent market volatility.
The Aster DM Healthcare–QCIL merger has created Aster DM Quality Care (AsterDM), establishing one of India's largest hospital platforms. As reported by Motilal Oswal, the merged entity operates 39 hospitals and approximately 10,600 operational beds across 28 cities. The platform has demonstrated significant expansion potential, with capacity to scale beyond 15,000 beds by FY30 through a balanced approach combining brownfield, greenfield, and asset-light strategies. The quarter also saw the QCIL merger finally take shape, backed by Blackstone and TPG, bringing Aster, CARE Hospitals, Evercare, and KIMSHEALTH under one roof. Motilal Oswal expects the merger to deliver a 10-15% uplift in EBITDA through centralised procurement, supply-chain optimisation, shared clinical resources and corporate cost rationalisation. Significant synergy potential from centralised procurement, supply-chain optimisation, shared clinical resources, and corporate cost rationalisation could support margin expansion, while greater scale should improve referrals, bargaining power, and asset utilisation, driving higher operating leverage.
The company's growth strategy is anchored by a cluster-led approach that leverages Kerala's mature, high-margin operations while expanding into faster-growing markets. According to Motilal Oswal's analysis, the Karnataka/Maharashtra and AP/Telangana footprint provides both earnings stability and long-term growth runway. Kerala remains the largest contributor, accounting for 53% of FY26 hospital revenue before the merger, supported by mature assets, quaternary care, and medical value travel. Motilal expects growth to be driven by the 454-bed Trivandrum expansion and other brownfield additions. Mature assets remain a significant earnings base, contributing around 65% to the June quarter's revenue. The QCIL merger meaningfully deepens regional diversification by bringing complementary hospital networks under one roof, creating a genuinely pan-India platform with stronger potential for cross-cluster referrals. Motilal Oswal expects revenue, EBITDA and PAT to grow at CAGRs of 19.5%, 25% and 33% respectively over FY26-28, with revenue projected to reach ₹13,200 crore and EBITDA ₹30.7 billion by FY28. This growth trajectory will be aided by procurement, clinical and cost synergies from the QCIL merger, supported by higher patient volumes, improving occupancy, case mix and merger synergies.
Motilal Oswal expects Aster DM's revenue, EBITDA and Profit After Tax (PAT) to grow at a Compounded Annual Growth Rate (CAGR) of 19.5%, 25% and 33% respectively over financial year 2026-2029, reaching figures of ₹13,200 crore, ₹3,070 crore and ₹1,560 crore respectively. The brokerage values Aster DM at 27 times its 12-month forward EBITDA estimate of ₹27.7 billion, arriving at the target price of ₹910. In its bull-case scenario, the brokerage sees the stock reaching ₹1,110, implying a 46% upside from current levels, assuming faster integration of Quality Care India, stronger merger benefits, higher hospital occupancy and revenue per occupied bed, as well as greater contribution from medical value tourism and complex-care services. Conversely, in the bear-case scenario, the target price is ₹735, implying an 8% downside, assuming slower realization of merger benefits, delays in adding new hospital capacity, weaker occupancy and continued cost pressures following the merger. While the merger has resulted in a net debt of ₹11.6 billion from a cash surplus of ₹5 billion, the brokerage expects free cash to reduce net debt, subject to M&A opportunities.
Despite the positive brokerage coverage, Aster DM Quality Care shares declined 0.23% to ₹745.65 on Tuesday, indicating mixed market sentiment toward the merger announcement. Of the 15 analysts covering the stock, 13 have a 'buy' rating and one each have 'hold' and 'sell' ratings, as reported by CNBC TV18. The stock has demonstrated strong performance with 24% gains year-to-date, reflecting investor confidence in the company's growth prospects. Key risks identified by Motilal Oswal include delays in synergy realisation as one of the key risks as it could weigh on margins, delays in expansion could defer growth and weaken the return on capital employed while regulatory changes and price caps could put pressure on profitability. The stock has gained 22.98% so far this year and 19.69% over the past year, showing consistent long-term performance despite recent volatility.
